Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | DTYMK | P23919 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249336 | 0.86 | POLB (0.52) | POLBDTYMKGPR119OPRD1OPRK1 | |
| SCHEMBL16836010 | 0.84 | GPR4 (0.41) | GPR119OPRD1OPRK1NAMPTSYK | |
| SCHEMBL4013541 | 0.84 | POLB (0.56) | POLBDTYMKGPR119OPRD1OPRK1 | |
| SCHEMBL3436213 | 0.84 | POLB (0.50) | POLBDTYMKGPR119OPRD1OPRK1 | |
| SCHEMBL3787005 | 0.84 | POLB (0.50) | POLBDTYMKGPR119OPRD1OPRK1 | |
| SCHEMBL17586467 | 0.82 | POLB (0.41) | POLBGPR119OPRD1OPRK1NAMPT | |
| SCHEMBL5467346 | 0.82 | PKLR (0.52) | POLBDTYMKGPR119OPRD1OPRK1 | |
| SCHEMBL1587985 | 0.82 | MEN1 (0.40) | POLBOPRD1OPRK1CHRM2 | |
| SCHEMBL5824222 | 0.80 | POLB (0.44) | POLBDTYMKGPR119OPRD1OPRK1 | |
| SCHEMBL5473953 | 0.79 | GPR119 (0.53) | POLBDTYMKGPR119OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| CN-116490186-A | Compounds for targeted degradation of RET | C4医药公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4192458-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-20110092529-A1 | 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092529-A1 | 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092529-A1 | 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists | OXTR, PRLHR, KISS1R | POLB 3177/4885DTYMK 3367/4885GPR119 277/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | POLB 3875/4885DTYMK 1326/4885GPR119 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.